Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,683
  • Shares Outstanding, K 4,864
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,830 K
  • 60-Month Beta 1.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.45
  • Low Estimate -0.52
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +78.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.19 +7.52%
on 09/24/20
4.18 -17.96%
on 08/26/20
-0.73 (-17.55%)
since 08/25/20
3-Month
3.19 +7.52%
on 09/24/20
5.31 -35.40%
on 07/31/20
-1.27 (-27.02%)
since 06/25/20
52-Week
3.19 +7.52%
on 09/24/20
19.60 -82.50%
on 01/10/20
-4.57 (-57.15%)
since 09/25/19

Most Recent Stories

More News
Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract...

CYCC : 3.43 (+3.00%)
CYCCP : 5.51 (+3.96%)
Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial...

CYCC : 3.43 (+3.00%)
Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second...

CYCC : 3.43 (+3.00%)
Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET -

CYCC : 3.43 (+3.00%)
Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first...

CYCC : 3.43 (+3.00%)
Cyclacel Announces Closing of $20 Million Public Offering

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the...

CYCC : 3.43 (+3.00%)
Company News for Apr 21, 2020

Companies In The News Are: CYCC, CODX, NBY, EXEL

EXEL : 23.84 (+2.58%)
CYCC : 3.43 (+3.00%)
NBY : 0.7180 (-1.45%)
CODX : 14.34 (+4.06%)
Organizations Begin Testing Treatments to Mitigate the Viral Threat

As the viral pandemic continues to spread, so too does the world's collective uncertainty regarding when and how quickly we will return to normalcy. In the meantime, the number of infected in the United...

BKLLF : 0.0440 (+25.00%)
CODE.CN : 0.050 (unch)
OPK : 3.22 (+4.89%)
OPGN : 2.06 (-0.48%)
CYCC : 3.43 (+3.00%)
OSUR : 11.24 (+5.59%)
CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the...

CYCC : 3.43 (+3.00%)
Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines today announced that it entered into an agreement with...

CYCC : 3.43 (+3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CYCC with:

Business Summary

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside...

See More

Key Turning Points

2nd Resistance Point 3.56
1st Resistance Point 3.50
Last Price 3.43
1st Support Level 3.33
2nd Support Level 3.22

See More

52-Week High 19.60
Fibonacci 61.8% 13.33
Fibonacci 50% 11.39
Fibonacci 38.2% 9.46
Last Price 3.43
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar